List view / Grid view

News

Sanofi reports positive Phase 3 results for Toujeo®

19 June 2014 | By Sanofi

Sanofi announced that, in a pooled analysis, investigational therapy Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL) consistently showed significantly fewer low blood sugar events (hypoglycemia)...

Teva reaches settlements in NUVIGIL® patent case

18 June 2014 | By Teva

Teva Pharmaceutical Industries Ltd. announced that it has reached settlements with Sandoz, Actavis, Lupin and Apotex with respect to U.S. Patent 7,132,570 for Teva’s wakefulness product, NUVIGIL® (armodafinil) tablet...

Bristol-Myers Squibb announces dividend

18 June 2014 | By Bristol-Myers Squibb

The Board of Directors of Bristol-Myers Squibb Company declared a quarterly dividend of thirty-six cents per share on the $.10 par value Common Stock of the corporation...

European Medicines Agency validates Marketing Authorization Applications for AbbVie’s investigational, all-oral, interferon-free therapy for the treatment of genotype 1 chronic hepatitis C

17 June 2014 | By AbbVie

AbbVie announced that the Marketing Authorization Applications for its investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 hepatitis C virus infection have been validated and are under accelerated assessment by the European Medicines Agency...